Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis.

M Takamori, M Motomura, N Kawaguchi, Y Nemoto, T Hattori, H Yoshikawa, K Otsuka

Journal: Neurology 2004;62(10):1894-6

PMID: 15159506

Abstract

Anti-ryanodine receptor (RyR) antibodies were measured in sera from 33 myasthenia gravis (MG) patients using three peptides from the human RyR1 sequence, two C-terminal peptides included in the functional calcium release channel, and an N-terminal peptide implicated in ion-conduction. Antibodies were more frequently positive against the two C-terminal peptides, particularly in thymoma-associated MG. In a preliminary open trial with FK506, immunosuppressant and enhancer of RyR-related sarcoplasmic calcium release, the authors observed the sustained benefits in anti-RyR-positive MG patients.

Address: Neurological Center, Kanazawa-Nishi Hospital, Kanazawa, Japan. [email protected]

DOI: 10.1212/01.wnl.0000125254.99397.68

Link outs

Free resources

Medical:

https://medlineplus.gov/myastheniagravis.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Adult, Aged, Autoantibodies, Autoantigens, Combined Modality Therapy, Enzyme-Linked Immunosorbent Assay, Epitopes, Female, Humans, Immunosuppressive Agents, Male, Middle Aged, Myasthenia Gravis, Receptors, Cholinergic, Ryanodine Receptor Calcium Release Channel, Tacrolimus, Thymectomy, Thymoma, Thymus Neoplasms, Treatment Outcome